MedPath

A study investigating the extraction of nicotine and flavors from tobacco-free nicotine pouches

Not Applicable
Completed
Conditions
Not Applicable
Tobacco/nicotine use
Registration Number
ISRCTN30119403
Lead Sponsor
Swedish Match
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
35
Inclusion Criteria

1. Willing and able to give written informed consent for participation in the study
2. Male or female subject aged =19 years
3. Subject who has used oral tobacco/nicotine products for =1 year, with a minimum daily consumption of five or more snus pouches, and is willing and able to use brands with nicotine content =1%
4. Women of child bearing potential (WOCBP) must be willing to use a sufficient contraceptive method for the duration of the study, this includes mechanical barrier
(e.g., a male condom or a female diaphragm), combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal anticonception associated with inhibition of ovulation [oral, injectable, implantable], IUD or IUS. Sexual abstinence is allowed when this is the preferred and usual lifestyle of the subject

Exclusion Criteria

1. Any surgical or medical condition including abnormal salivation (also pharmaceutically induced), or history thereof, which, in the judgment of the Investigator, might interfere with the absorption of the IP or may either put the subject at risk because of participation in the study, influence the results, or the subject’s ability to participate in the study
2. Any clinically significant illness in the 28 days prior to the first IP administration
3. A history or presence of untreated diagnosed hypertension or any cardiovascular disease
4. Female subject currently breast feeding, pregnant or planning to get pregnant during the study
5. Positive screen for drugs of abuse or alcohol at screening or on admission to the unit prior to first administration of the IP
6. Current or history of alcohol abuse and/or use of anabolic steroids or drugs of abuse, as judged by the Investigator
7. Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Extracted dose of nicotine from each portion is measured by using GC-MS analysis and calculated by subtracting the residual amount after use from the mean of 10 unused portions. Used portions are freezed after dosing and analysis using GC-MS is performed at the end of the trial.
Secondary Outcome Measures
NameTimeMethod
1. The extracted dose of flavor components are measured using GC-MS analysis and calculated by subtracting the residual amount after use from the mean of 10 unused portions. Used portions are freezed after dosing and analysis using GC-MS is performed at the end of the study<br>2. Self-report of potential adverse events (AEs, frequency, intensity and seriousness) measured throughout the study
© Copyright 2025. All Rights Reserved by MedPath